Session 5: GLP-1 RA’s (Non-Insulin Injectables): Focus on Renal and CV Effects

Wednesday, June 1, 2022, 12:30 PM - 1:45 PM

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician (1.00 hours)

Date and Time: Session 5: Wednesday, June 1st, 2022 @ 12:30pm-1:45pm PST 
Zoom Webinar ID: 976 0959 8851 
Webinar Link: https://washington.zoom.us/j/97609598851

Talk Title: GLP-1 RA’s (Non-Insulin Injectables): Focus on Renal and CV Effects

To go back to the main course page, please click here.

1. Describe insulin sparing injectable medications available for the treatment of type 2 diabetes in terms of mechanism of action, efficacy, side effects, CV/renal disease benefit, and use in liver/NASH.
2. Discuss differences within the class including average a1c and weight reduction.
3. Explain how to initiate and mitigate side-effect profile.

After registering, learners can access the OnDemand content available following these steps:

1. Locate "MyCME" on your screen
2. Select "Tests"
3. Locate the preferred session of "OT2207 CardioMetabolic ECHO" and click "Pre-Test" to begin. Additional instructions are contained within each session.
4. In order to receive a certificate, you must complete the evaluation following the post-test.

Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Washington School of Medicine designates this other activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each session is worth 1.0 credit. You can participate in the live, enduring material and/or both. You can only claim credit once per session (live vs recorded).  In order to receive credit, learners must attend the live webinar OR watch the recorded content.  For webinar recordings, learners must answer pre/post test questions with a 70% pass rate to receive credit.  All learners must complete the post-session assessment to claim credit.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 24 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the University of Washington School of Medicine’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACPE Accreditation

The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. Each session is worth 1.0 CPE. To receive credit you must complete the post-session evaluation for each session you attend. At the conclusion of the series, participants should be able to combat clinical and medication inertia around cardiometabolic therapy.

ACPE activity number: 0130-9999-22-293-H01-P, 0130-9999-22-293-L01-P

Speaker Disclosures: Virtual Advisory Board: Eli LIlly & Co.

Planner Disclosure(s):

• Nicole Ehrhardt, MD is on the Advisory Board for Dexcom and NovoNordisk; Education Grant from NovoNordisk and Merck; Investigator with Dexcom
• Savitha Subramanian, MD is on the Advisory Board for Abbott Diabetes Care; former Advisory Board for Akcea Therapeutics and Amarni
• Laura Montour, MD: No Disclosures
• Lorena Casas-Wright, MD: No Disclosures
• Nayan Arora, MD: No Disclosures

All relevant financial relationships have been mitigated.

Mitigation of Relevant Financial Relationships

University of Washington School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Wednesday, June 1, 2022

We would like to thank NovoNordisk for providing an unrestricted educational grant to support the Cardiometabolic ECHO Program.